Liraglutide
Also known as: Victoza
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). It was the first GLP-1 analog approved for obesity and carries an FDA boxed warning for the risk of thyroid C-cell tumors. Pediatric indications include type 2 diabetes in patients ≥10 years (Victoza) and obesity in patients ≥12 years with BMI ≥95th percentile (Saxenda).
Pricing for Liraglutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
No COAs on file for Liraglutide
No third-party tests indexed yet. Phase 2 will surface more vendor evidence as the dataset grows.
32 citations indexed for Liraglutide
Study · 2026
The GLP-1 Receptor Agonist Liraglutide Promotes Anticancer Activities in MCF7 Breast and PC-3 Prostate Cancer Cells by Modulating Glycolysis, Oxidative Stress and Adipokines
This research explored the anticancer activities of the glucagon-like peptide-1 receptor agonist (GLP1Ra) liraglutide using MCF7 breast and PC-3 prostate cancer cell lines. The study focused on key molecular pathways related to glycolysis and oxidative stress alongside adipokine profiles.
Study · 2026
Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli
Glucagon-like peptide-1 (GLP-1), a 31-amino acid incretin hormone, is widely used in the treatment of type 2 diabetes mellitus due to its glucose-dependent insulinotropic activity.
animal · 2026
Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways
Background Diabetic complications extend beyond metabolic disturbances to include end-organ damage, with emerging evidence including lung and skeletal muscle dysfunction as under recognized manifestations.
Study · 2026
A single centre retrospective study of the long‑term weight and pregnancy-related outcomes in women of reproductive age before and after liraglutide exposure
Background The impact of GLP‑1 receptor agonist exposure prior to pregnancy on pregnancy-related outcomes remains unclear, with studies reporting mixed findings.
Study · 2026
Incidence of Barrett's esophagus and esophageal cancer following sleeve gastrectomy versus liraglutide therapy
Background Sleeve gastrectomy has consistently been linked to gastroesophageal reflux disease and Barrett's esophagus. At the same time, the long-term effects of glucagon-like peptide-1 receptor agonists, particularly short-acting agents such as liraglutide, are less well understood.
Study · 2026
Anti-inflammatory and anabolic effects of liraglutide on 3D inflammatory osteoarthritic spheroid and scaffold models of human chondrocytes
Objective Osteoarthritis (OA) is a prevalent age-related joint disease characterized by low-grade inflammation and progressive cartilage degeneration.